95967-46-7

Upstream product

• 74530-56-6 tert-butyl 4-chloroacetoacetate 
• 100-51-6 benzyl alcohol 
• 540-88-5 acetic acid tert-butyl ester 
• 19810-31-2 Benzyloxyacetyl chloride 
• 31600-43-8 methyl 2-(benzyloxy)acetate 
• 30379-55-6 benzyloxyacetic acid 

Downstream Products

• 147849-59-0 tert-Butyl (S)-4-benzyloxy-3-hydroxybutanoate 
• 147849-58-9 tert-Butyl (R)-4-benzyloxy-3-hydroxybutanoate 
• 95967-28-5 tert.-butyl 4-<3(R)-benzoylamino-2-azetidinon-4(R)-yloxy>-acetoacetate 
• 95991-81-4 tert.-butyl (6R,7R)-7-benzoylamino-3-chloro-8-oxo-5-oxa-1-azabicyclo<4.2.0>oct-2-ene-2-carboxylate 
• 95967-30-9 tert.-butyl (6R,7R)-7-benzoylamino-3-hydroxy-8-oxo-5-oxa-1-azabicyclo<4.2.0>oct-2-ene-2-carboxylate 
• 95967-31-0 tert.-butyl (6R,7R)-7-benzoylamino-3-methoxy-8-oxo-5-oxa-1-azabicyclo<4.2.0>oct-2-ene-2-carboxylate 
• 95967-29-6 tert.-butyl 4-<3(R)-benzoylamino-2-azetidinon-4(R)-yloxy>-2-diazo-3-oxo-butanoate 
• 1332856-04-8 l 
• 1332856-07-1 C₂₄H₁₉FN₂O₅S 
• 1616277-90-7 C₂₄H₂₁FN₂O₆S 
• 1616277-98-5 ethyl 3-(benzyloxy)-1-((tert-butoxycarbonyl)(methyl)amino)-5-(5-(4-fluorobenzyl)-1,3,4-thiadiazol-2-yl)-4-oxo-1,4-dihydropyridine-2-carboxylate 
• 1616277-99-6 3-(benzyloxy)-1-((tert-butoxycarbonyl)(methyl)amino)-5-(5-(4-fluorobenzyl)-1,3,4-thiadiazol-2-yl)-4-oxo-1,4-dihydropyridine-2-carboxylic acid 
• 1616278-00-2 tert-butyl (3-(benzyloxy)-2-(ethylcarbamoyl)-5-(5-(4-fluorobenzyl)-1,3,4-thiadiazol-2-yl)-4-oxopyridin-1(4H)-yl)(methyl)carbamate 

Relevant academic research and scientific papers

SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS

The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, Y, R1, R2 and R11 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS

Disclosed are Spirocyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, where A, B, X, Y, R1, R2 and R11 are as defined herein. Composition comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject are also disclosed.

4-PYRIDINONETRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS

The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R1, R2, R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.

SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR

Provided is a substituted spiropyrido[1,2-a]pyrazine derivative or a pharmaceutically acceptable salt thereof, which is useful as an anti-HIV agent. The present invention relates to a compound represented by the following formula [I] or [II] or a pharmace

1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyradine Derivatives and Use Thereof as HIV Integrase Inhibitor

[Problem] Provided is a novel 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative or a pharmaceutically acceptable salt thereof, or a solvate thereof, which is useful as an anti-HIV agent. [Solving Means] The present invention provides a compound repre

PYRROLOPYRIDAZINE DERIVATIVES

The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-α mediated diseases.

Process for the preparation of 7-acylamino-3-hydroxy-cephem-4-carboxylic acids and 7-acylamino-3-hydroxy-1-dethia-1-oxacephem-4-carboxylic acids

A process for the preparation of a 7-acylamino-3-hydroxy-2-cephem-4-carboxylic acid, 7-acylamino-3-hydroxy-1-dethia-1-oxa-3-cephem-4-carboxylic acid or derivative thereof of the general formula STR1 in which R1 is hydrogen or optionally substituted alkyl, alkenyl, alkinyl, aralkyl, aryl, heteroaryl, heteroaralkyl, aryloxyalkyl, heteroaryloxyalkyl, alkoxyalkyl, arylthioalkyl, heteroarylthioalkyl, alkylthioalkyl, alkoxy, aryloxy, alkylthio or arylthio, R2 is hydrogen, a carboxy-protective group or a pharmaceutically useful ester radical, and X is sulphur or oxygen, which comprises: (a) reacting a compound of the formula STR2 with (i) a compound of the formula STR3 in which R2 and X have the abovementioned meaning and Y represents diazo (N2) or hydrogen (H2) in an inert solvent in the presence of a Lewis acid or proton acid catalyst, or (ii) a compound of the formula to form an intemediate compound having a triple bond, and hydrating the triple bond, the compounds thus obtained, for Y being hydrogen (H2)--(in case of Y=diazo (N2) directly the compounds of general formula (2) are obtained) thereby to produce a compound of the formula STR4 (b) reacting such compound with an azide in a solvent in the presence of a base to give a compound of the formula STR5 (c) converting said compound to the desired product by (i) irradiation in an inert solvent, or (ii) warming in the presence of a catalyst. The end products are, or can be converted to, known β-lactam antibiotics.

A CONVERGENT SCHEME FOR THE STEREOSELECTIVE SYNTHESIS OF 3'-NOR-1-OXACEPHEMS

A convergent approach to the construction of the 3-hydroxy-oxacephems 1, valuable intermediates for the synthesis of 3'-nor-1-oxacephems, is presented.The key step utilizes the Lewis acid catalyzed stereoselective ring-opening of the oxazoline 2 by an app